SK BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89,800 KRW | +1.58% |
|
+1.70% | -10.56% |
| May. 10 | SK Biopharmaceuticals Turns to Profit in Q1 as Sales Jump 88% | MT |
| Jan. 30 | SK Biopharmaceuticals Swings to Profit in Q4 | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,234,939 | 7,612,048 | 5,646,385 | 7,862,650 | 7,032,530 | - | - |
| Enterprise Value (EV) 2 | 12,865 | 7,293 | 5,353 | 7,863 | 6,892 | 6,802 | 6,715 |
| P/E ratio | -49 x | 117 x | -40.5 x | -239 x | 228 x | 54.5 x | 34.6 x |
| Yield | - | - | - | - | - | - | 0.06% |
| Capitalization / Revenue | 515 x | 18.2 x | 22.9 x | 22.2 x | 14.4 x | 10.7 x | 8.92 x |
| EV / Revenue | 501 x | 17.4 x | 21.7 x | 22.2 x | 14.1 x | 10.4 x | 8.52 x |
| EV / EBITDA | -55.6 x | 68.4 x | -45.3 x | -354 x | 112 x | 37.6 x | 25.3 x |
| EV / FCF | -58 x | -75 x | -32.5 x | - | 164 x | 53.1 x | 43 x |
| FCF Yield | -1.72% | -1.33% | -3.08% | - | 0.61% | 1.88% | 2.32% |
| Price to Book | 34.9 x | 17.1 x | 17.8 x | - | 21.7 x | 16.2 x | 11.2 x |
| Nbr of stocks (in thousands) | 78,313 | 78,313 | 78,313 | 78,313 | 78,313 | - | - |
| Reference price 3 | 169,000 | 97,200 | 72,100 | 100,400 | 89,800 | 89,800 | 89,800 |
| Announcement Date | 2/8/21 | 2/8/22 | 2/9/23 | 1/29/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 123.9 | 25.69 | 418.6 | 246.2 | 354.9 | 489.6 | 654.7 | 788.5 |
| EBITDA 1 | - | -231.2 | 106.6 | -118.1 | -22.2 | 61.32 | 181.1 | 265.4 |
| EBIT 1 | - | -239.5 | 94.96 | -131.1 | -37.09 | 45.39 | 167.5 | 274.6 |
| Operating Margin | - | -932.32% | 22.68% | -53.24% | -10.45% | 9.27% | 25.58% | 34.83% |
| Earnings before Tax (EBT) 1 | - | -240.2 | 71.28 | -142.5 | -42.58 | 36.61 | 151.8 | 253.2 |
| Net income 1 | - | -247.7 | 64.85 | -139.4 | -33.93 | 30.55 | 116.5 | 203.3 |
| Net margin | - | -964.34% | 15.49% | -56.64% | -9.56% | 6.24% | 17.8% | 25.78% |
| EPS 2 | -1,100 | -3,448 | 828.0 | -1,780 | -420.0 | 393.5 | 1,649 | 2,596 |
| Free Cash Flow 3 | - | -221,749 | -97,188 | -164,831 | - | 42,144 | 128,170 | 156,000 |
| FCF margin | - | -863,221.34% | -23,214.67% | -66,955.81% | - | 8,608.17% | 19,576.79% | 19,785.37% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 68,727.49% | 70,777.21% | 58,775.51% |
| FCF Conversion (Net income) | - | - | - | - | - | 137,933.57% | 109,984.48% | 76,751.03% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 50.00 |
| Announcement Date | 4/14/20 | 2/8/21 | 2/8/22 | 2/9/23 | 1/29/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 164 | 23.95 | 230.7 | 41.14 | 53.43 | 88.83 | 62.77 | 60.78 | 77.01 | 90.34 | 126.8 | 114 | 111.9 | 124.6 | 142.8 | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | 15.1 | 13.8 | 17.5 | 21.2 | - |
| EBIT 1 | 10.85 | -49.94 | 134.4 | -37.14 | -40.07 | -9.247 | -44.62 | -22.66 | -18.94 | -10.71 | 15.21 | 10.3 | 6.922 | 13.88 | 19.63 | - |
| Operating Margin | 6.62% | -208.5% | 58.23% | -90.26% | -74.99% | -10.41% | -71.09% | -37.27% | -24.59% | -11.86% | 12% | 9.03% | 6.19% | 11.14% | 13.75% | - |
| Earnings before Tax (EBT) 1 | - | -44.5 | 52.68 | -35.01 | - | -16.62 | -46.55 | -2.494 | -25.05 | -19.82 | 4.796 | 7.758 | 1.3 | 10.57 | 15.17 | - |
| Net income 1 | 61.99 | -44.27 | 47.13 | -35.21 | - | -14.96 | -43.86 | -2.369 | -23.34 | -13.93 | 5.708 | 12.83 | 1.95 | 11 | 14.42 | - |
| Net margin | 37.81% | -184.85% | 20.42% | -85.56% | - | -16.84% | -69.88% | -3.9% | -30.31% | -15.42% | 4.5% | 11.26% | 1.74% | 8.83% | 10.11% | - |
| EPS 2 | - | - | - | -450.0 | -580.0 | -191.0 | -560.0 | -30.00 | -298.0 | -235.0 | 86.00 | -32.91 | 15.63 | 152.0 | 186.0 | 159.7 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/10/21 | 11/11/21 | 2/8/22 | 5/16/22 | 8/11/22 | 11/10/22 | 2/9/23 | 5/10/23 | 8/10/23 | 11/9/23 | 1/29/24 | 5/9/24 | - | - | - | - |
1KRW in Billions2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 370 | 319 | 293 | - | 141 | 231 | 318 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | - | -221,749 | -97,188 | -164,831 | - | 42,144 | 128,170 | 156,000 |
| ROE (net income / shareholders' equity) | - | -135% | 19.8% | -36.7% | - | 11.9% | 31.7% | 37.5% |
| ROA (Net income/ Total Assets) | - | -77.1% | 11.3% | -21.3% | - | 3.89% | 14.7% | 21.3% |
| Assets 1 | - | 321.3 | 571.9 | 653.9 | - | 785.1 | 795.1 | 955.8 |
| Book Value Per Share 3 | - | 4,840 | 5,672 | 4,042 | - | 4,139 | 5,560 | 8,050 |
| Cash Flow per Share 3 | - | -2,936 | - | -2,042 | - | 705.0 | 1,703 | 2,394 |
| Capex 1 | - | 11 | 4.32 | 4.91 | - | 8.6 | 8.33 | 8.68 |
| Capex / Sales | - | 42.91% | 1.03% | 1.99% | - | 1.76% | 1.27% | 1.1% |
| Announcement Date | 4/14/20 | 2/8/21 | 2/8/22 | 2/9/23 | 1/29/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
89,800
KRW
Average target price
106,333
KRW
Spread / Average Target
+18.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.56% | 5.13B | |
| +7.91% | 72.81B | |
| +12.64% | 9.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B | |
| -0.50% | 1.64B | |
| +0.07% | 1.59B |
- Stock Market
- Equities
- A326030 Stock
- Financials SK Biopharmaceuticals Co., Ltd.
